Petros Pharmaceuticals, Inc.: management transactions · United States · SEC (Form 4)

About Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc. (ticker PTPI) is a United States-based pharmaceutical company that was historically listed on Nasdaq and, after its Nasdaq trading suspension in 2025, continued trading on the OTC Markets under the PTPI symbol. For investors, that market migration is an important signal: the company remains public, but it has a much smaller market profile and a more speculative risk/reward setup than a normal NYSE/Nasdaq issuer. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1815903/000110465926060359/tmb-20260331x10q.htm?utm_source=openai)) Petros’ core strategy centers on expanding access to selected prescription medicines through the over-the-counter, or OTC, channel. The company says it aims to become a leading innovator in the self-care space by helping transform Rx products into OTC treatment options. In recent SEC filings, Petros also described a proprietary integrated technology platform under development, combining a SaaS layer designed to help pharmaceutical companies operationalize and commercialize an Rx-to-OTC switch with a potential Software as a Medical Device (SaMD) component to support consumer self-selection and compliance with FDA requirements. That makes Petros more than a conventional branded-drug story; it is trying to position itself at the intersection of pharma, digital health, and regulatory workflow software. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1815903/000110465926043822/tmb-20251231x10k.htm?utm_source=openai)) The company’s operating history is tied to the December 2020 merger of Metuchen Pharmaceuticals, LLC with Neurotrope, Inc., which marked a strategic reorientation of the business. Its corporate footprint is in Cranford, New Jersey, United States, and its leadership roster reflects a mix of pharmaceutical, financial, and commercial experience. From an investor-relations standpoint, Petros presents itself as a healthcare platform company focused on a future in which access to medication becomes more efficient and consumer-driven. ([petrospharma.com](https://petrospharma.com/?utm_source=openai)) On the product side, SEC filings indicate that Petros licensed an FDA-approved PDE-5 inhibitor prescription medication for erectile dysfunction from Vivus, Inc. That product exposure gives the company a foothold in a recognizable therapeutic area, but Petros’ broader ambition is to create value through the Rx-to-OTC transition process rather than by scaling a large diversified pharmaceutical portfolio. In practical terms, this means the company’s competitive edge depends on regulatory execution, product positioning, and whether its commercialization platform can attract outside adoption. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1815903/000110465926060359/tmb-20260331x10q.htm?utm_source=openai)) Petros operates in a highly competitive and regulated segment, where small companies often face funding constraints, long development timelines, and binary regulatory milestones. Its recent filings point to continued operating losses, cost discipline, and a need to preserve capital, while 2025 financing activity helped support liquidity. The company also disclosed that, after the Nasdaq delisting, its shares continued trading publicly on the OTC market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1815903/000110465926060359/tmb-20260331x10q.htm?utm_source=openai)) From a market-position perspective, Petros should be viewed as a niche U.S. healthcare microcap with an ambitious but still unproven model. For French-speaking investors in Europe, the key takeaways are clear: the story is about OTC innovation, FDA-regulated execution, and a potentially scalable software-enabled commercialization model, but it comes with elevated balance-sheet, listing, and execution risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1815903/000110465926043822/tmb-20251231x10k.htm?utm_source=openai))